PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20809412-8	2011	RESULTS: The results revealed that target cells" cytotoxic sensitivity to natural killer (NK) cells increased in association with up-regulation of NKG2DLs on tumor cells after incubation with sorafenib and sunitinib.	Sorafenib	192-201	killer cell lectin like receptor C1	Homo sapiens	147-151	
20809412-9	2011	Furthermore, up-regulation in sunitinib group was much higher than in sorafenib group when it came to the expressions of NKG2DLs on tumor cells.	Sorafenib	70-79	killer cell lectin like receptor C1	Homo sapiens	121-125	
20809412-11	2011	CONCLUSIONS: Our research revealed for the first time that sorafenib and sunitinib could up-regulate NKG2DLs on tumor cells resulting in markedly increased tumor cells cytotoxic sensitivity to NK cells, which suggested that combining usage of molecular targeted agents and ACI may result in great benefits in clinical practice for the therapy-resistant cases and drug-resistant relapse.	Sorafenib	59-68	killer cell lectin like receptor C1	Homo sapiens	101-105